Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 8, 2010, Pages 473-477

  Laudes, M ^a   Oberhauser, F ^a   Schulte, D M ^a   Schilbach, K ^a   Freude, S ^a   Bilkovski, R ^a   Schulz, O ^a   Faust, M ^a   Krone, W ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

autoimmunity; diabetes; immune system; incretins

Indexed keywords

ATTRACTIN; CD14 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; RNA; SITAGLIPTIN;

ADULT; ARTICLE; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; INSULIN TREATMENT; MALE; METABOLIC PARAMETERS; MONOCYTE; MULTIPLEX POLYMERASE CHAIN REACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANTIGENS, CD14; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MONOCYTES; OBESITY; PYRAZINES; TRIAZOLES;

EID: 77956976665     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0030-1249014     Document Type: Article

References (24)

1. Ahrén B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002 25 69-875
2. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007 298 194-206
3. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008 117 2340-2350
4. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996 137 2968-2978
5. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001 107 1255-1262
6. Deacon CF, Holst JJ. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. Int J Biochem Cell Biol 2006 38 831-844
7. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003 144 5149-5158
8. Holst JJ, Orskov C. Incretin hormones an update. Scand J Clin Lab Invest Suppl 2001 234 75-85
9. Ishihara H, Maechler P, Gjinovci A, et al. Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. Nat Cell Biol 2003 5 330-335
10. Lambeir AM, Durinx C, Scharpé S, et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003 40 209-294
11. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007 356 1517-1526
12. Näslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999 23 304-311
13. Nauck M, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986 29 46-52
14. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986 63 492-498
15. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993 36 741-744 (Pubitemid 23218642)
16. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997 273 E981-E988
17. Pacheco R, Martinez-Navio JM, Lejeune M, et al. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci U S A 2005 102 9583-9588
18. Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003 72 603-612
19. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001 86 4382-4389
20. Vilsbll T, Agers H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003 88 220-224
21. Wrenger S, Faust J, Friedrich D, et al. Attractin, a dipeptidyl peptidase IV/CD26-like enzyme, is expressed on human peripheral blood monocytes and potentially influences monocyte function. J Leukoc Biol 2006 80 621-629
22. Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999 48 2270-2276
23. Yamagata S, Tomita K, Sato R, et al. Interleukin-18-deficient mice exhibit diminished chronic inflammation and airway remodelling in ovalbumin-induced asthma model. Clin Exp Immunol 2008 154 295-304
24. Zhou J, Wang X, Pineyro MA, et al. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 1999 48 2358-2366